Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Hypertriglyceridemia
Interventions: MAR001, Placebo; Drug
Lead sponsor: Marea Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Dyslipidemia
Interventions: Atorvastatin, ABT335, ER Niacin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: LIB003; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Interventions: RN0361; Drug
Lead sponsor: Ikaria Bioscience Pty Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Tamarac, Florida • Versailles, Kentucky • Dilworth, Minnesota + 3 more

Conditions: Lipid Disorders
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemia
Interventions: Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo, Bococizumab 75mg placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Chandler, Arizona • Lincoln, California • Los Angeles, California + 25 more

Conditions: Hypercholesterolemia, Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Interventions: SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, Genetic testing for SLCO1B1*5 allele; Genetic
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Travis Air Force Base, California • Durham, North Carolina

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: torcetrapib/atorvastatin, ezetimibe/simvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 123
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more

Conditions: Diabetes, Hypertension, Hyperlipidemia
Interventions: Health coaching by medical assistants in primary care; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Hypercholesterolaemia
Interventions: alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio

Conditions: Carotid Stenosis
Interventions: Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS; Procedure · Device · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 100 Years
Enrollment: 2,486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 154
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 112 more

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • New Hyde Park, New York + 5 more

Conditions: HIV Infections, Hyperlipidemia
Interventions: oyster mushroom; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypercholesterolemia, Postmenopause
Interventions: L-arginine, Estrogen; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemia
Interventions: A: NK-104-CR 8 mg, B: Pitavastatin IR 4 mg, C: Pitavastatin IR 8 mg; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cardiovascular Diseases, Cholesterol, LDL
Interventions: Population Health Management Intervention; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Flagstaff, Arizona • Chicago, Illinois

Conditions: HIV Infections, Hyperlipidemia
Interventions: Rosiglitazone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Hypertriglyceridemia (sHTG)
Interventions: evinacumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Boca Raton, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and rosuvastatin, Rosuvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 82
States / cities: Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more

Conditions: Spinal Cord Injuries
Interventions: Seated control (CON), Moderate intensity continuous (MICT), High intensity interval training (HIIT), Circuit resistance training (CRT), Liquid Meal; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heart Diseases, Cardiovascular Disease
Interventions: Whole Milk-Skim Milk, Skim Milk-Whole Milk; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiovascular Diseases
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

Genes Involved in Lipid Disorders

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

Genetically Guided Statin Therapy

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Antihyperlipidemic Effects of Oyster Mushrooms

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women

A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers

Reducing Disparities in Primary Prevention of Cardiovascular Disease

Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

Energetic Response to Feeding and Exercise in SCI

Gauging Outcomes of Total Milk Ingestion on Lipid and gControl

Evaluation of Atorvastatin Treatment on Carotid Plaque.